Tricida (TCDA) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Tricida (TCDA) Reports In-Line Q3 EPS

Tricida Announces Third Quarter 2019 Financial Results

November 14, 2019 4:08 PM EST

FDA Accepts New Drug Application for Veverimer

Webcast Today at 4:30 pm Eastern Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and nine months ended September 30, 2019 and provided an update on key initiatives.

Recent... More